Next-generation antibody-drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer

Cancer Biol Med. 2023 Oct 12;20(10):689-694. doi: 10.20892/j.issn.2095-3941.2023.0286.

Authors

Lei-Jie Dai^#^{1

2}, Yu-Wei Li^#^{1

2}, Ding Ma^{1

2}, Zhi-Ming Shao^{1

2}, Yi-Zhou Jiang^{1

2}

Affiliations

¹ Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
² Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai 200032, China.

^# Contributed equally.

PMID: 37823691
PMCID: PMC10618949
DOI: 10.20892/j.issn.2095-3941.2023.0286

No abstract available

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Breast Neoplasms* / drug therapy
Female
Humans
Immunoconjugates* / pharmacology
Immunoconjugates* / therapeutic use
Receptor, ErbB-2

Substances

Immunoconjugates
Receptor, ErbB-2
Antibodies, Monoclonal, Humanized